{
    "clinical_study": {
        "@rank": "100706", 
        "arm_group": [
            {
                "arm_group_label": "Remifentanyl", 
                "arm_group_type": "Active Comparator", 
                "description": "Group R 0.1-0.3 mic/kg/ min remifentanil infusion other names: Ultiva"
            }, 
            {
                "arm_group_label": "esmolol", 
                "arm_group_type": "Experimental", 
                "description": "Grup E 500 micg/kg/min lading dose after 50-500 \u03bccg/kg/dk esmolol infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "In this prospective randomized study we aimed to compare the effects of esmolol and\n      remifentanil on intraoperative bleeding surgical field conditions in nasal surgery"
        }, 
        "brief_title": "A Comparison of Esmolol and Remifentanil to Reduce Blood Loss", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "condition": "Deviation Septum Nasal", 
        "detailed_description": {
            "textblock": "60 patients with ASA I-IIphysical status assigned for septoplasty will be enrolled in this\n      prospective randomized trial. A standardized anesthesia induction and intubation with\n      propofol and rocuronium will be used. Patients will be randomized in two groups. Group\n      Esmolol (Group E n=30) will receive esmolol 500 mic kg-1 loading dose and a 50-500 mic kg-1\n      min-1 infusion and Group Remifentanil (Group R n=30) will receive remifentanil 0.1-0.3 mic\n      kg-1 min-1 infusion to induce controlled hypotension. A 50-60 mmHg mean arterial pressure\n      and a minimum 50 beat min-1 heart rate is targeted. Heart rate, blood pressures, peripheral\n      oxygen saturation and bispectral index spectrum (BIS) will be recorded. Anesthesia\n      maintenance will be provided with O2/N2O and desflurane-propofol balanced anesthesia and a\n      BIS value 40-60 is targeted. The quality of the surgical field will be assessed by the\n      surgeon by using a 10 point visual analog scale (B1) and a 6 point scale (B2) during surgery\n      with 5 minute intervals. The amount of bleeding will be calculated at the end of surgery\n      from the amount of blood and irrigation fluid collected in the suction tube. All\n      complications and side effects will be recorded."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  ASA I-II,\n\n          -  between age 20-60\n\n        Exclusion Criteria:\n\n          -  patients having bleeding disorders,\n\n          -  arrhythmia,\n\n          -  hypertension,\n\n          -  endocrine, liver or kidney disease and\n\n          -  those who are on antihypertensive,\n\n          -  anticoagulant drugs"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 4, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01752959", 
            "org_study_id": "RAcikgozEsmolol"
        }, 
        "intervention": [
            {
                "arm_group_label": "Remifentanyl", 
                "description": "0.1-0.3 micg/kg/min Remifentanil iv infusion", 
                "intervention_name": "Remifentanil", 
                "intervention_type": "Drug", 
                "other_name": "Ultiva"
            }, 
            {
                "arm_group_label": "esmolol", 
                "description": "500 \u03bccg/kg/dk esmolol iv lading dose after 50-500 \u03bccg/kg/dk esmolol iv infusion", 
                "intervention_name": "Esmolol", 
                "intervention_type": "Drug", 
                "other_name": "Brevibloc"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Esmolol", 
                "Remifentanil"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "December 17, 2012", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06110"
                    }, 
                    "name": "Diskapi Yildirim Beyazit Training and Research Hospital"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "muratalper@hotmail.com", 
                    "last_name": "Murat Alper, Proffesor", 
                    "phone": "03125962242"
                }, 
                "facility": {
                    "address": {
                        "city": "Ankara", 
                        "country": "Turkey", 
                        "zip": "06610"
                    }, 
                    "name": "Diskapi Yildirim Beyazit Training and Research Hospital"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Turkey"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Comparison of Esmolol and Remifentanil on Intraoperative Bleeding and Surgical Field Conditionsin Nasal Surgery", 
        "overall_contact": {
            "last_name": "Ruveyda D Acikgoz, Trainee", 
            "phone": "0903125962554"
        }, 
        "overall_contact_backup": {
            "email": "dilek.yazicioglu@hotmail.com", 
            "last_name": "Dilek Yazicioglu, Specialist", 
            "phone": "0903125962553"
        }, 
        "overall_official": {
            "affiliation": "Ankara Diskapi Yildirim Beyazit Teaching and Research Hospital, Turkey.", 
            "last_name": "Ruveyda D Ac\u0131kgoz, Trainee", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Turkey: Ministry of Health", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2012", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "controlled hypotension in nasal surgery", 
            "measure": "the difference between group regarding blood loss", 
            "safety_issue": "No", 
            "time_frame": "intraoperative"
        }, 
        "reference": [
            {
                "PMID": "11212044", 
                "citation": "Degoute CS, Ray MJ, Manchon M, Dubreuil C, Banssillon V. Remifentanil and controlled hypotension; comparison with nitroprusside or esmolol during tympanoplasty. Can J Anaesth. 2001 Jan;48(1):20-7."
            }, 
            {
                "PMID": "22185726", 
                "citation": "Shen PH, Weitzel EK, Lai JT, Wormald PJ, Ho CS. Intravenous esmolol infusion improves surgical fields during sevoflurane-anesthetized endoscopic sinus surgery: a double-blind, randomized, placebo-controlled trial. Am J Rhinol Allergy. 2011 Nov-Dec;25(6):e208-11. doi: 10.2500/ajra.2011.25.3701."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01752959"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Diskapi Teaching and Research Hospital", 
            "investigator_full_name": "Dondu Ruveyda Acikgoz", 
            "investigator_title": "Medical Doctor Trainee in Anesthesiology and Reanimation", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "side effects: more than 20% change in blood pressure and heart rate, treatment includes atropin, ephedrin, nitroglyserine", 
            "measure": "the difference between groups regarding side effects and treatments", 
            "safety_issue": "No", 
            "time_frame": "intraoperative"
        }, 
        "source": "Diskapi Teaching and Research Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Diskapi Teaching and Research Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}